Cosmo Pharmaceuticals N.V./€COPN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company headquartered in Dublin, Ireland, with a focus on developing and manufacturing treatments for gastrointestinal diseases, specifically targeting the large intestine. The company's core products include therapies for ulcerative colitis, colon infections, and related areas. Cosmo's notable products, such as Lialda/Mezavant and Eleview, highlight its focus on advanced treatments that enhance colonic drug delivery and endoscopic visualization. The company has strategically concentrated its research and development to specialize in its therapeutic areas, leveraging its proprietary Methacrylate-Copolymer technology. Cosmo Pharmaceuticals also engages in partnerships to extend its market reach and continues to expand its influence globally through strategic collaborations and licensing agreements.
Ticker
€COPN
Sector
Primary listing
XGAT
Employees
325
Headquarters
Dublin, Ireland
COPN Metrics
BasicAdvanced
€1.2bn
-
-€0.23
1.55
€2.10
2.85%
Price and volume
Market cap
€1.2bn
Beta
1.55
52-week high
€142.00
52-week low
€58.52
Average daily volume
9.7k
Dividend rate
€2.10
Financial strength
Current ratio
7.181
Quick ratio
5.801
Long term debt to equity
0.727
Total debt to equity
0.872
Interest coverage (TTM)
-57.80%
Profitability
EBITDA (TTM)
5.061
Gross margin (TTM)
48.53%
Net profit margin (TTM)
-3.46%
Operating margin (TTM)
-6.66%
Effective tax rate (TTM)
-280.17%
Revenue per employee (TTM)
€320,000
Management effectiveness
Return on assets (TTM)
-0.69%
Return on equity (TTM)
-0.70%
Valuation
Price to revenue (TTM)
11.29
Price to book
2.3
Price to tangible book (TTM)
3.66
Price to free cash flow (TTM)
-65.539
Free cash flow yield (TTM)
-1.53%
Free cash flow per share (TTM)
-1.124
Dividend yield (TTM)
2.85%
Forward dividend yield
2.85%
Growth
Revenue change (TTM)
-60.95%
Earnings per share change (TTM)
-102.78%
3-year revenue growth (CAGR)
0.68%
10-year revenue growth (CAGR)
5.56%
3-year earnings per share growth (CAGR)
-40.05%
10-year earnings per share growth (CAGR)
-35.10%
3-year dividend per share growth (CAGR)
25.99%
10-year dividend per share growth (CAGR)
4.14%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
FAQs